Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men (2012)
- Authors:
- Lu, Beibei
- Viscidi, Raphael P.
- Wu, Yougui
- Lee, Ji-Hyun
- Nyitray, Alan G.
- Villa, Luisa L.
- Lazcano-Ponce, Eduardo - Instituto Nacional de Salud Pública (INSP-MX)
- Silva, Roberto J. Carvalho da
- Baggio, Maria Luiza
- Quiterio, Manuel - Instituto Nacional de Salud Pública (INSP-MX)
- Salmeron, Jorge
- Smith, Danelle C.
- Abrahamsen, Martha E.
- Papenfuss, Mary R.
- Stockwell, Heather G.
- Giuliano, Anna R.
- Autor USP: VILLA, LUISA LINA - FM
- Unidade: FM
- DOI: 10.1158/0008-5472.CAN-11-0751
- Subjects: VACINAS VIRAIS; IMUNIZAÇÃO; ONCOGENES; NEOPLASIAS DO COLO UTERINO; ANTICORPOS; BIOMARCADORES; HPV (IMUNOLOGIA)
- Language: Inglês
- Imprenta:
- Source:
- Título: Cancer Research
- ISSN: 0008-5472
- Volume/Número/Paginação/Ano: v. 72, n. 3, p. 676-685, 2012
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
-
ABNT
LU, Beibei et al. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men. Cancer Research, v. 72, n. 3, p. 676-685, 2012Tradução . . Disponível em: https://doi.org/10.1158/0008-5472.CAN-11-0751. Acesso em: 29 dez. 2025. -
APA
Lu, B., Viscidi, R. P., Wu, Y., Lee, J. -H., Nyitray, A. G., Villa, L. L., et al. (2012). Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men. Cancer Research, 72( 3), 676-685. doi:10.1158/0008-5472.CAN-11-0751 -
NLM
Lu B, Viscidi RP, Wu Y, Lee J-H, Nyitray AG, Villa LL, Lazcano-Ponce E, Silva RJC da, Baggio ML, Quiterio M, Salmeron J, Smith DC, Abrahamsen ME, Papenfuss MR, Stockwell HG, Giuliano AR. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men [Internet]. Cancer Research. 2012 ; 72( 3): 676-685.[citado 2025 dez. 29 ] Available from: https://doi.org/10.1158/0008-5472.CAN-11-0751 -
Vancouver
Lu B, Viscidi RP, Wu Y, Lee J-H, Nyitray AG, Villa LL, Lazcano-Ponce E, Silva RJC da, Baggio ML, Quiterio M, Salmeron J, Smith DC, Abrahamsen ME, Papenfuss MR, Stockwell HG, Giuliano AR. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men [Internet]. Cancer Research. 2012 ; 72( 3): 676-685.[citado 2025 dez. 29 ] Available from: https://doi.org/10.1158/0008-5472.CAN-11-0751 - Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study
- POP-Brazil study protocol: a nationwide cross-sectional evaluation of the prevalence and genotype distribution of human papillomavirus (HPV) in Brazil
- Association of HPV infection and Chlamydia trachomatis seropositivity in cases of cervical neoplasia in Midwest Brazil
- Human Papillomavirus (HPV) 6, 11, 16, and 18 Seroprevalence Is Associated with Sexual Practice and Age: Results from the Multinational HPV Infection in Men Study (HIM Study)
- Planning cancer control in Latin America and the Caribbean
- Accuracy of p53 Codon 72 Polymorphism Status Determined by Multiple Laboratory Methods: A Latent Class Model Analysis
- Human papillomavirus type 16 viral load measurement as a predictor of infection clearance
- The Natural History of Genital Human Papillomavirus Among HIV-Negative Men Having Sex With Men and Men Having Sex With Women
- Mini-plenary session 2 rolling out HPV vaccination: successes, challenges and lessons learnt
- Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas
Informações sobre o DOI: 10.1158/0008-5472.CAN-11-0751 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
